Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015 (2015), Article ID 308574, 14 pages
http://dx.doi.org/10.1155/2015/308574
Review Article

Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy

1Cancer Science Institute of Singapore, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228
2Department of Haematology-Oncology, National University Hospital, Singapore 119228

Received 12 August 2015; Accepted 5 October 2015

Academic Editor: Michael H. Kershaw

Copyright © 2015 Vinod Vijay Subhash et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H.-R. Shin, M. C. Carlos, and C. Varghese, “Cancer control in the Asia Pacific region: current status and concerns,” Japanese Journal of Clinical Oncology, vol. 42, no. 10, Article ID hys077, pp. 867–881, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Biondi, R. Persiani, F. Cananzi et al., “R0 resection in the treatment of gastric cancer: room for improvement,” World Journal of Gastroenterology, vol. 16, no. 27, pp. 3358–3370, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. D. Cunningham, N. Starling, S. Rao et al., “Capecitabine and oxaliplatin for advanced esophagogastric cancer,” The New England Journal of Medicine, vol. 358, no. 1, pp. 36–46, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. J. S. Park, J. Y. Lim, S. K. Park et al., “Prognostic factors of second and third line chemotherapy using 5-FU with platinum, irinotecan, and taxane for advanced gastric cancer,” Cancer Research and Treatment, vol. 43, no. 4, pp. 236–243, 2011. View at Publisher · View at Google Scholar · View at Scopus
  5. Y.-J. Bang, E. Van Cutsem, A. Feyereislova et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. Y. Ishimine, A. Goto, Y. Watanabe et al., “Loss of HER2 positivity after trastuzumab in HER2-positive gastric cancer: is change in HER2 status significantly frequent?” Case Reports in Gastrointestinal Medicine, vol. 2015, Article ID 132030, 6 pages, 2015. View at Publisher · View at Google Scholar
  7. C. S. Fuchs, J. Tomasek, C. J. Yong et al., “Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial,” The Lancet, vol. 383, no. 9911, pp. 31–39, 2014. View at Publisher · View at Google Scholar · View at Scopus
  8. H. Wilke, K. Muro, E. Van Cutsem et al., “Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial,” The Lancet Oncology, vol. 15, no. 11, pp. 1224–1235, 2014. View at Publisher · View at Google Scholar · View at Scopus
  9. T. Waddell, I. Chau, D. Cunningham et al., “Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial,” The Lancet Oncology, vol. 14, no. 6, pp. 481–489, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. F. Lordick, Y.-K. Kang, H.-C. Chung et al., “Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial,” The Lancet Oncology, vol. 14, no. 6, pp. 490–499, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. M. Mayr, K. Becker, N. Schulte et al., “Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma,” BMC Cancer, vol. 12, article 587, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. P. B. Chapman, S. P. D'Angelo, and J. D. Wolchok, “Rapid eradication of a bulky melanoma mass with one dose of immunotherapy,” The New England Journal of Medicine, vol. 372, no. 21, pp. 2073–2074, 2015. View at Publisher · View at Google Scholar
  13. S. Matsueda and D. Y. Graham, “Immunotherapy in gastric cancer,” World Journal of Gastroenterology, vol. 20, no. 7, pp. 1657–1666, 2014. View at Publisher · View at Google Scholar · View at Scopus
  14. L. A. Emens and G. Middleton, “The interplay of immunotherapy and chemotherapy: harnessing potential synergies,” Cancer Immunology Research, vol. 3, no. 5, pp. 436–443, 2015. View at Publisher · View at Google Scholar
  15. D. M. Pardoll, “The blockade of immune checkpoints in cancer immunotherapy,” Nature Reviews Cancer, vol. 12, no. 4, pp. 252–264, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. A. Cimino-Mathews, J. B. Foote, and L. A. Emens, “Immune targeting in breast cancer,” Oncology, vol. 29, pp. 375–385, 2015. View at Google Scholar
  17. R. D. Schreiber, L. J. Old, and M. J. Smyth, “Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion,” Science, vol. 331, no. 6024, pp. 1565–1570, 2011. View at Publisher · View at Google Scholar · View at Scopus
  18. D. Mittal, M. M. Gubin, R. D. Schreiber, and M. J. Smyth, “New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape,” Current Opinion in Immunology, vol. 27, no. 1, pp. 16–25, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. O. S. Qureshi, Y. Zheng, K. Nakamura et al., “Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4,” Science, vol. 332, no. 6029, pp. 600–603, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. A. Pedoeem, I. Azoulay-Alfaguter, M. Strazza, G. J. Silverman, and A. Mor, “Programmed death-1 pathway in cancer and autoimmunity,” Clinical Immunology, vol. 153, no. 1, pp. 145–152, 2014. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Sznol, “Blockade of the B7-H1/PD-1 pathway as a basis for combination anticancer therapy,” Cancer Journal, vol. 20, no. 4, pp. 290–295, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. C. E. Weber and P. C. Kuo, “The tumor microenvironment,” Surgical Oncology, vol. 21, no. 3, pp. 172–177, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Ishimoto, H. Sawayama, H. Sugihara, and H. Baba, “Interaction between gastric cancer stem cells and the tumor microenvironment,” Journal of Gastroenterology, vol. 49, no. 7, pp. 1111–1120, 2014. View at Publisher · View at Google Scholar · View at Scopus
  24. Z. N. Oltvai and A.-L. Barabási, “Systems biology. Life's complexity pyramid,” Science, vol. 298, no. 5594, pp. 763–764, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. T. Blankenstein, P. G. Coulie, E. Gilboa, and E. M. Jaffee, “The determinants of tumour immunogenicity,” Nature Reviews Cancer, vol. 12, no. 4, pp. 307–313, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Amedei, C. Della Bella, E. Silvestri, D. Prisco, and M. M. D'Elios, “T cells in gastric cancer: friends or foes,” Clinical and Developmental Immunology, vol. 2012, Article ID 690571, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Ishigami, S. Natsugoe, K. Tokuda et al., “Tumor-associated macrophage (TAM) infiltration in gastric cancer,” Anticancer Research, vol. 23, no. 5, pp. 4079–4083, 2003. View at Google Scholar · View at Scopus
  28. J. B. Mitchem, D. J. Brennan, B. L. Knolhoff et al., “Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses,” Cancer Research, vol. 73, no. 3, pp. 1128–1141, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Amedei, M. Benagiano, C. della Bella, E. Niccolai, and M. M. D'Elios, “Novel immunotherapeutic strategies of gastric cancer treatment,” Journal of Biomedicine and Biotechnology, vol. 2011, Article ID 437348, 17 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Palucka and J. Banchereau, “Cancer immunotherapy via dendritic cells,” Nature Reviews Cancer, vol. 12, no. 4, pp. 265–277, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Gilboa, “DC-based cancer vaccines,” The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1195–1203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Ishigami, S. Natsugoe, K. Tokuda et al., “Prognostic value of intratumoral natural killer cells in gastric carcinoma,” Cancer, vol. 88, no. 3, pp. 577–583, 2000. View at Google Scholar · View at Scopus
  33. E. Niccolai, A. Taddei, D. Prisco, and A. Amedei, “Gastric cancer and the epoch of immunotherapy approaches,” World Journal of Gastroenterology, vol. 21, no. 19, pp. 5778–5793, 2015. View at Publisher · View at Google Scholar
  34. U. Petrausch, C. H. Poehlein, S. M. Jensen et al., “Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects,” Current Molecular Medicine, vol. 9, no. 6, pp. 673–682, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Zorzetto, G. Maddalo, D. Basso, and F. Farinati, “Immunotherapy for gastric premalignant lesions and cancer,” Immunotherapy, vol. 4, no. 6, pp. 587–599, 2012. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Kono, A. Takahashi, F. Ichihara et al., “Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial,” Clinical Cancer Research, vol. 8, no. 6, pp. 1767–1771, 2002. View at Google Scholar · View at Scopus
  37. N. Sadanaga, H. Nagashima, K. Mashino et al., “Dendritic cell vaccination with MAGE peptide is a novel therapeutic approach for gastrointestinal carcinomas,” Clinical Cancer Research, vol. 7, no. 8, pp. 2277–2284, 2001. View at Google Scholar · View at Scopus
  38. T. W. Kim, C.-F. Hung, D. Boyd et al., “Enhancing DNA vaccine potency by combining a strategy to prolong dendritic cell life with intracellular targeting strategies,” Journal of Immunology, vol. 171, no. 6, pp. 2970–2976, 2003. View at Publisher · View at Google Scholar · View at Scopus
  39. T. H. Kang, J. H. Lee, K. H. Noh et al., “Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments,” International Journal of Cancer, vol. 120, no. 8, pp. 1696–1703, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. S.-B. He, K. Sun, L. Wang, D.-C. Li, and Y.-Y. Zhang, “GM-CSF gene-modified dendritic cell vaccine enhances antitumor immunity in vitro,” Zhonghua Zhong Liu Za Zhi, vol. 32, no. 6, pp. 410–414, 2010. View at Google Scholar · View at Scopus
  41. J. H. Kim, T. H. Kang, K. H. Noh et al., “Enhancement of DC vaccine potency by activating the PI3K/AKT pathway with a small interfering RNA targeting PTEN,” Immunology Letters, vol. 134, no. 1, pp. 47–54, 2010. View at Publisher · View at Google Scholar · View at Scopus
  42. J. H. Kim, T. H. Kang, K. H. Noh et al., “Blocking the immunosuppressive axis with small interfering RNA targeting interleukin (IL)-10 receptor enhances dendritic cell-based vaccine potency,” Clinical and Experimental Immunology, vol. 165, no. 2, pp. 180–189, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. J. A. Ajani, J. R. Hecht, L. Ho et al., “An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study,” Cancer, vol. 106, no. 9, pp. 1908–1916, 2006. View at Publisher · View at Google Scholar · View at Scopus
  44. O. E. Rahma and S. N. Khleif, “Therapeutic vaccines for gastrointestinal cancers,” Gastroenterology and Hepatology, vol. 7, no. 8, pp. 517–564, 2011. View at Google Scholar · View at Scopus
  45. Y. Sato, H. Shomura, Y. Maeda et al., “Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide,” Cancer Science, vol. 94, no. 9, pp. 802–808, 2003. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Yang, Z.-H. Li, J.-J. Zhou et al., “Preparation and antitumor effects of nanovaccines with MAGE-3 peptides in transplanted gastric cancer in mice,” Chinese Journal of Cancer, vol. 29, no. 4, pp. 359–364, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. T. Masuzawa, Y. Fujiwara, K. Okada et al., “Phase I/II study of S-1 plus cisplatin combined with peptide vaccines for human vascular endothelial growth factor receptor 1 and 2 in patients with advanced gastric cancer,” International Journal of Oncology, vol. 41, no. 4, pp. 1297–1304, 2012. View at Publisher · View at Google Scholar · View at Scopus
  48. S. Kim, K. Iizuka, H. L. Aguila, I. L. Weissman, and W. M. Yokoyama, “In vivo natural killer cell activities revealed by natural killer cell-deficient mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 97, no. 6, pp. 2731–2736, 2000. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Cheng, Y. Chen, W. Xiao, R. Sun, and Z. Tian, “NK cell-based immunotherapy for malignant diseases,” Cellular and Molecular Immunology, vol. 10, no. 3, pp. 230–252, 2013. View at Publisher · View at Google Scholar · View at Scopus
  50. C. J. Voskens, R. Watanabe, S. Rollins, D. Campana, K. Hasumi, and D. L. Mann, “Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity,” Journal of Experimental & Clinical Cancer Research, vol. 29, article 134, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Coca, J. Perez-Piqueras, D. Martinez et al., “The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma,” Cancer, vol. 79, no. 12, pp. 2320–2328, 1997. View at Google Scholar · View at Scopus
  52. F. R. Villegas, S. Coca, V. G. Villarrubia et al., “Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer,” Lung Cancer, vol. 35, no. 1, pp. 23–28, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. D. Rosso, M. P. Rigueiro, P. Kassab et al., “Correlation of natural killer cells with the prognosis of gastric adenocarcinoma,” Arquivos Brasileiros de Cirurgia Digestiva, vol. 25, no. 2, pp. 114–117, 2012. View at Publisher · View at Google Scholar · View at Scopus
  54. H. Saito, S. Takaya, T. Osaki, and M. Ikeguchi, “Increased apoptosis and elevated Fas expression in circulating natural killer cells in gastric cancer patients,” Gastric Cancer, vol. 16, no. 4, pp. 473–479, 2013. View at Publisher · View at Google Scholar · View at Scopus
  55. X.-T. Wu, J.-Q. Liu, X.-T. Lu et al., “The enhanced effect of lupeol on the destruction of gastric cancer cells by NK cells,” International Immunopharmacology, vol. 16, no. 2, pp. 332–340, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. J. Wang, K. A. Reiss, R. Khatri, E. Jaffee, and D. Laheru, “Immune therapy in GI malignancies: a review,” Journal of Clinical Oncology, vol. 33, no. 16, pp. 1745–1753, 2015. View at Publisher · View at Google Scholar
  57. M. E. Dudley, J. R. Wunderlich, P. F. Robbins et al., “Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes,” Science, vol. 298, no. 5594, pp. 850–854, 2002. View at Publisher · View at Google Scholar · View at Scopus
  58. E. Y. Woo, C. S. Chu, T. J. Goletz et al., “Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer,” Cancer Research, vol. 61, no. 12, pp. 4766–4772, 2001. View at Google Scholar · View at Scopus
  59. C. H. June, “Principles of adoptive T cell cancer therapy,” The Journal of Clinical Investigation, vol. 117, no. 5, pp. 1204–1212, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. A. Mackensen, N. Meidenbauer, S. Vogl, M. Laumer, J. Berger, and R. Andreesen, “Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma,” Journal of Clinical Oncology, vol. 24, no. 31, pp. 5060–5069, 2006. View at Publisher · View at Google Scholar · View at Scopus
  61. Y. J. Kim, J. Lim, J. S. Kang et al., “Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells,” Archives of Pharmacal Research, vol. 33, no. 11, pp. 1789–1795, 2010. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Sangiolo, “Cytokine induced killer cells as promising immunotherapy for solid tumors,” Journal of Cancer, vol. 2, no. 1, pp. 363–368, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. T. Hoshino, N. Seki, M. Kikuchi et al., “Hla class-I-restricted and tumor-specific CTL in tumor-infiltrating lymphocytes of patients with gastric cancer,” International Journal of Cancer, vol. 70, no. 6, pp. 631–638, 1997. View at Publisher · View at Google Scholar · View at Scopus
  64. J. Jiang, N. Xu, C. Wu et al., “Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells,” Anticancer Research, vol. 26, no. 3, pp. 2237–2242, 2006. View at Google Scholar · View at Scopus
  65. C. Wu, J. Jiang, L. Shi, and N. Xu, “Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer,” Anticancer Research, vol. 28, no. 6, pp. 3997–4002, 2008. View at Google Scholar · View at Scopus
  66. X. Du, R. Jin, N. Ning et al., “In vivo distribution and antitumor effect of infused immune cells in a gastric cancer model,” Oncology Reports, vol. 28, no. 5, pp. 1743–1749, 2012. View at Publisher · View at Google Scholar · View at Scopus
  67. M. E. Dudley, J. R. Wunderlich, T. E. Shelton, J. Even, and S. A. Rosenberg, “Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients,” Journal of Immunotherapy, vol. 26, no. 4, pp. 332–342, 2003. View at Publisher · View at Google Scholar · View at Scopus
  68. R. B. Alexander and S. A. Rosenberg, “Long-term survival of adoptively transferred tumor-infiltrating lymphocytes in mice,” The Journal of Immunology, vol. 145, no. 5, pp. 1615–1620, 1990. View at Google Scholar · View at Scopus
  69. S. A. Rosenberg, J. R. Yannelli, J. C. Yang et al., “Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2,” Journal of the National Cancer Institute, vol. 86, no. 15, pp. 1159–1166, 1994. View at Publisher · View at Google Scholar · View at Scopus
  70. M. Tomšová, B. Melichar, I. Sedláková, and I. Šteiner, “Prognostic significance of CD3+ tumor-infiltrating lymphocytes in ovarian carcinoma,” Gynecologic Oncology, vol. 108, no. 2, pp. 415–420, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. J. Galon, A. Costes, F. Sanchez-Cabo et al., “Type, density, and location of immune cells within human colorectal tumors predict clinical outcome,” Science, vol. 313, no. 5795, pp. 1960–1964, 2006. View at Publisher · View at Google Scholar · View at Scopus
  72. A. Amedei, E. Niccolai, M. Benagiano et al., “Ex vivo analysis of pancreatic cancer-infiltrating T lymphocytes reveals that ENO-specific Tregs accumulate in tumor tissue and inhibit Th1/Th17 effector cell functions,” Cancer Immunology, Immunotherapy, vol. 62, no. 7, pp. 1249–1260, 2013. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Amedei, E. Niccolai, C. D. Bella et al., “Characterization of tumor antigen peptide-specific T cells isolated from the neoplastic tissue of patients with gastric adenocarcinoma,” Cancer Immunology, Immunotherapy, vol. 58, no. 11, pp. 1819–1830, 2009. View at Publisher · View at Google Scholar · View at Scopus
  74. C. A. Ramos and G. Dotti, “Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy,” Expert Opinion on Biological Therapy, vol. 11, no. 7, pp. 855–873, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. D. M. Barrett, N. Singh, D. L. Porter, S. A. Grupp, and C. H. June, “Chimeric antigen receptor therapy for cancer,” Annual Review of Medicine, vol. 65, pp. 333–347, 2014. View at Publisher · View at Google Scholar · View at Scopus
  76. H. Singh, J. S. E. Moyes, M. H. Huls, and L. J. N. Cooper, “Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor,” Cancer Gene Therapy, vol. 22, pp. 95–100, 2015. View at Publisher · View at Google Scholar · View at Scopus
  77. M. H. Kershaw, J. A. Westwood, C. Y. Slaney, and P. K. Darcy, “Clinical application of genetically modified T cells in cancer therapy,” Clinical & Translational Immunology, vol. 3, article e16, 2014. View at Publisher · View at Google Scholar
  78. O. Goldberger, I. Volovitz, A. Machlenkin, E. Vadai, E. Tzehoval, and L. Eisenbach, “Exuberated numbers of tumor-specific T cells result in tumor escape,” Cancer Research, vol. 68, no. 9, pp. 3450–3457, 2008. View at Publisher · View at Google Scholar · View at Scopus
  79. S. Kailayangiri, B. Altvater, J. Meltzer et al., “The ganglioside antigen G D2 is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting,” British Journal of Cancer, vol. 106, no. 6, pp. 1123–1133, 2012. View at Publisher · View at Google Scholar · View at Scopus
  80. D. Hollyman, J. Stefanski, M. Przybylowski et al., “Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy,” Journal of Immunotherapy, vol. 32, no. 2, pp. 169–180, 2009. View at Publisher · View at Google Scholar · View at Scopus
  81. R. J. Brentjens, I. Rivière, J. H. Park et al., “Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias,” Blood, vol. 118, no. 18, pp. 4817–4828, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. J. H. Pinthus, T. Waks, K. Kaufman-Francis et al., “Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes,” Cancer Research, vol. 63, no. 10, pp. 2470–2476, 2003. View at Google Scholar · View at Scopus
  83. C. H. J. Lamers, S. Sleijfer, A. G. Vulto et al., “Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience,” Journal of Clinical Oncology, vol. 24, no. 13, pp. e20–e22, 2006. View at Publisher · View at Google Scholar · View at Scopus
  84. A. A. Chekmasova, T. D. Rao, Y. Nikhamin et al., “Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen,” Clinical Cancer Research, vol. 16, no. 14, pp. 3594–3606, 2010. View at Publisher · View at Google Scholar · View at Scopus
  85. A. M. Intlekofer and C. B. Thompson, “At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy,” Journal of Leukocyte Biology, vol. 94, no. 1, pp. 25–39, 2013. View at Publisher · View at Google Scholar · View at Scopus
  86. S. Mocellin, C. Benna, and P. Pilati, “Coinhibitory molecules in cancer biology and therapy,” Cytokine and Growth Factor Reviews, vol. 24, no. 2, pp. 147–161, 2013. View at Publisher · View at Google Scholar · View at Scopus
  87. L. Chen and D. B. Flies, “Molecular mechanisms of T cell co-stimulation and co-inhibition,” Nature Reviews Immunology, vol. 13, no. 4, pp. 227–242, 2013. View at Publisher · View at Google Scholar · View at Scopus
  88. A. Ito, S. Kondo, K. Tada, and S. Kitano, “Clinical development of immune checkpoint inhibitors,” BioMed Research International, vol. 2015, Article ID 605478, 12 pages, 2015. View at Publisher · View at Google Scholar
  89. D. H. Wang, L. Guo, and X. H. Wu, “Checkpoint inhibitors in immunotherapy of ovarian cancer,” Tumor Biology, vol. 36, no. 1, pp. 33–39, 2015. View at Publisher · View at Google Scholar
  90. C. E. Rudd, A. Taylor, and H. Schneider, “CD28 and CTLA-4 coreceptor expression and signal transduction,” Immunological Reviews, vol. 229, no. 1, pp. 12–26, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. E. Sharon, H. Streicher, P. Goncalves, and H. X. Chen, “Immune checkpoint inhibitors in clinical trials,” Chinese Journal of Cancer, vol. 33, no. 9, pp. 434–444, 2014. View at Publisher · View at Google Scholar
  92. C. J. Nirschl and C. G. Drake, “Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy,” Clinical Cancer Research, vol. 19, no. 18, pp. 4917–4924, 2013. View at Publisher · View at Google Scholar · View at Scopus
  93. T. R. Simpson, F. Li, W. Montalvo-Ortiz et al., “Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma,” Journal of Experimental Medicine, vol. 210, no. 9, pp. 1695–1710, 2013. View at Publisher · View at Google Scholar · View at Scopus
  94. D. R. Leach, M. F. Krummel, and J. P. Allison, “Enhancement of antitumor immunity by CTLA-4 blockade,” Science, vol. 271, no. 5256, pp. 1734–1736, 1996. View at Publisher · View at Google Scholar · View at Scopus
  95. A. van Elsas, A. A. Hurwitz, and J. P. Allison, “Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation,” The Journal of Experimental Medicine, vol. 190, no. 3, pp. 355–366, 1999. View at Publisher · View at Google Scholar · View at Scopus
  96. S. A. Quezada, T. R. Simpson, K. S. Peggs et al., “Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts,” The Journal of Experimental Medicine, vol. 207, no. 3, pp. 637–650, 2010. View at Publisher · View at Google Scholar · View at Scopus
  97. C. Ralph, E. Elkord, D. J. Burt et al., “Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma,” Clinical Cancer Research, vol. 16, no. 5, pp. 1662–1672, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. D. Wilson, L. Hiller, and J. I. Geh, “Review of second-line chemotherapy for advanced gastric adenocarcinoma,” Clinical Oncology, vol. 17, no. 2, pp. 81–90, 2005. View at Publisher · View at Google Scholar · View at Scopus
  99. G. Goel and W. Sun, “Cancer immunotherapy in clinical practice—the past, present, and future,” Chinese Journal of Cancer, vol. 33, no. 9, pp. 445–457, 2014. View at Publisher · View at Google Scholar · View at Scopus
  100. R. S. Herbst, J.-C. Soria, M. Kowanetz et al., “Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients,” Nature, vol. 515, no. 7528, pp. 563–567, 2014. View at Publisher · View at Google Scholar · View at Scopus
  101. P. C. Tumeh, C. L. Harview, J. H. Yearley et al., “PD-1 blockade induces responses by inhibiting adaptive immune resistance,” Nature, vol. 515, no. 7528, pp. 568–571, 2014. View at Publisher · View at Google Scholar · View at Scopus
  102. K. Muro, Y. Bang, V. Shankaran et al., “LBA15: a phase 1B study of pembrolizumab (pembro; MK-3475) in patients (PTS) with advanced gastric cancer,” Annals of Oncology, vol. 25, supplement 4, 2014. View at Publisher · View at Google Scholar
  103. E. Romano and P. Romero, “The therapeutic promise of disrupting the PD-1/PD-L1 immune checkpoint in cancer: unleashing the CD8 T cell mediated anti-tumor activity results in significant, unprecedented clinical efficacy in various solid tumors,” Journal for Immunotherapy of Cancer, vol. 3, article 15, 2015. View at Publisher · View at Google Scholar
  104. M. A. Curran, W. Montalvo, H. Yagita, and J. P. Allison, “PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors,” Proceedings of the National Academy of Sciences of the United States of America, vol. 107, no. 9, pp. 4275–4280, 2010. View at Publisher · View at Google Scholar · View at Scopus
  105. J. Duraiswamy, K. M. Kaluza, G. J. Freeman, and G. Coukos, “Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors,” Cancer Research, vol. 73, no. 12, pp. 3591–3603, 2013. View at Publisher · View at Google Scholar · View at Scopus
  106. M. Noguchi, T. Sasada, and K. Itoh, “Personalized peptide vaccination: a new approach for advanced cancer as therapeutic cancer vaccine,” Cancer Immunology, Immunotherapy, vol. 62, no. 5, pp. 919–929, 2013. View at Publisher · View at Google Scholar · View at Scopus
  107. P. Sharma and J. P. Allison, “The future of immune checkpoint therapy,” Science, vol. 348, no. 6230, pp. 56–61, 2015. View at Publisher · View at Google Scholar
  108. D. S. Shin and A. Ribas, “The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?” Current Opinion in Immunology, vol. 33, pp. 23–35, 2015. View at Publisher · View at Google Scholar · View at Scopus
  109. K. M. Mahoney, G. J. Freeman, and D. F. McDermott, “The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma,” Clinical Therapeutics, vol. 37, no. 4, pp. 764–782, 2015. View at Publisher · View at Google Scholar
  110. Cancer Genome Atlas Research Network, “Comprehensive molecular characterization of gastric adenocarcinoma,” Nature, vol. 513, no. 7517, pp. 202–209, 2014. View at Publisher · View at Google Scholar
  111. A. Covre, S. Coral, A. M. Di Giacomo, P. Taverna, M. Azab, and M. Maio, “Epigenetics meets immune checkpoints,” Seminars in Oncology, vol. 42, no. 3, pp. 506–513, 2015. View at Publisher · View at Google Scholar
  112. W. Wang, W. Ji, H. Hu et al., “Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy,” Oncotarget, vol. 5, no. 1, pp. 150–160, 2014. View at Publisher · View at Google Scholar · View at Scopus